Erratum to: J Neurooncol DOI 10.1007/s11060-010-0329-z
The Abstract section of the original publication contains the following two errors:
-
right column, lines 6–7: “...then every 3 weeks at 100 mg/m2...” should read “...then every 4 weeks at 80 mg/m2...”.
-
right column, lines 16–17: “Progression-free survival at 6 months was 61%.” should read “Progression-free survival at 6 months was 39%.”.
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1007/s11060-010-0329-z.
Rights and permissions
Open Access This is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License ( https://creativecommons.org/licenses/by-nc/2.0 ), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
About this article
Cite this article
Addeo, R., Caraglia, M., De Santi, M.S. et al. Erratum to: A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma. J Neurooncol 102, 425 (2011). https://doi.org/10.1007/s11060-010-0415-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-010-0415-2